Catalyst
Slingshot members are tracking this event:
Novartis (NVS) to submit biosimilar Pegfilgrastim for bone marrow stimulation to FDA in early 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 03, 2019
Occurred Source:
https://www.novartis.com/news/media-releases/sandoz-resubmits-biosimilar-pegfilgrastim-application-us-fda
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Biosimilar, Pegfilgrastim, Fda Review, Bone Marrow Stimulation
